@article {10.3844/ajbbsp.2026.22.02.017,
article_type = {journal},
title = {Impact of CTLA-4 Inhibitor Combined with Chemotherapy on Immunoglobulin Levels and General Condition in Breast Cancer Patients},
author = {Cai, Ruiguang},
volume = {22},
number = {2},
year = {2026},
month = {Jul},
pages = {17-1},
doi = {10.3844/ajbbsp.2026.22.02.017},
url = {https://thescipub.com/abstract/ajbbsp.2026.22.02.017},
abstract = {This study conducted an evaluation of the CTLA-4 inhibitor ipilimumab plus standard chemotherapy on immunoglobulin levels, performance status, and Quality of Life (QoL) in patients with stage I-III Breast Cancer (BC) via a randomized controlled trial. 120 patients with stage I-III BC were randomly allocated to the experimental group (chemotherapy + ipilimumab) and the control group (chemotherapy), and the treatment cycle was 12 weeks. The results revealed that the combination treatment significantly increased the levels of serum IgG, IgA, and IgM (for example, IgG increased by 42.3%, P },
journal = {American Journal of Biochemistry and Biotechnology},
publisher = {Science Publications}
}